Inhibitors of HIV-1 protease: 10 years after

DOI: 10.1517/13543776.16.8.1067
Expert Opinion on Therapeutic Patents, 2006, 16, 1067-1091.

#	Paper	IF	Citations
19	Carbonic anhydrase inhibitors and activators and their use in therapy. *Expert Opinion on Therapeutic Patents*, **2006**, 16, 1627-1664	6.8	143
18	Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. *Journal of Virology*, **2007**, 81, 13845-51	6.6	135
17	Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones. *Journal of Medicinal Chemistry*, **2007**, 50, 4953-75	8.3	61
16	Kinetics and mechanism of the hydrolytic degradation of indinavir: intramolecular catalysis. *Journal of Pharmaceutical Sciences*, **2008**, 97, 3810-9	3.9	7
15	Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir. *Protein Science*, **2008**, 17, 1555-64	6.3	20
14	Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance. *Journal of Medicinal Chemistry*, **2008**, 51, 4839-43	8.3	82
13	Practical Synthesis of a HIV Integrase Inhibitor. *Organic Process Research and Development*, **2008**, 12, 1245-1252	3.9	9
12	Tipranavir: a novel protease inhibitor for HIV therapy. *Expert Review of Clinical Pharmacology*, **2009**, 2, 147-53	3.8	1
11	Evolution of tertiary carbinamine BACE-1 inhibitors: Abeta reduction in rhesus CSF upon oral dosing. *ChemMedChem*, **2009**, 4, 37-40	3.7	15
10	Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 7211-9	8.3	44
9	SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1885-9	2.9	22
8	Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PK. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 7429-34	2.9	14
7	Structure-based design of anti-infectives. *Annals of the New York Academy of Sciences*, **2010**, 1213, 20-45	6.5	18
6	Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors. *Journal of Physical Chemistry B*, **2010**, 114, 9663-76	3.4	34
5	Detailed atomistic analysis of the HIV-1 protease interface. *Journal of Physical Chemistry B*, **2011**, 115, 7045-57	3.4	15
4	Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design. *Journal of Medicinal Chemistry*, **2013**, 56, 5631-5	8.3	51
3	One-pot enyne ring-closing metathesis–Diels–Alder reactions for the synthesis of polycyclic sulfamides. *Tetrahedron*, **2014**, 70, 3700-3706	2.4	9

2	Unconventional approaches for the introduction of sulfur-based functional groups. *Organic and Biomolecular Chemistry*, **2021**, 19, 6926-6957	3.9	1
1	Kinetics of Bovine leukemia virus aspartic protease reveals its dimerization and conformational change. **2022**, 17, e0271671		